BMRN News and Press, BioMarin Pharmaceutical Inc. From 07/30/23

2023-07-30 17:35:00 ET BioMarin Pharmaceutical ( NASDAQ: BMRN ) is scheduled to announce Q2 earnings results on Monday, July 31st, after market close. The consensus EPS Estimate is $0.47 (+213.3% Y/Y) and the consensus Revenue Estimate is $595.24M (+11.5% Y/Y). Over th...

2023-07-22 05:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. U.S. equities advanced...

2023-07-17 10:57:40 ET Summary BioMarin's stocks have underperformed the S&P500 index recently due to the investor rotation from defensive sectors to riskier ones and potential slowdown in M&A activity in the biotechnology sector. Despite this, BioMarin's business remains ...

BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienai...

2023-06-30 18:08:43 ET Summary BioMarin Pharmaceutical Inc. received FDA approval for ROCTAVIAN for adults with severe Hemophilia A. Net product revenues of VOXZOGO grew by 346% year-over-year to $87.8 million. In the coming months U.S. and European Union will decide if VOXZOG...

2023-06-29 15:00:48 ET BioMarin Pharmaceutical ( NASDAQ: BMRN ) announced Thursday that the FDA approved its one-time gene therapy, Roctavian, as a treatment for adults with the bleeding disorder severe hemophilia A. The approval was based on data from a global Phase 3 study i...

U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A PR Newswire ROCTAVIAN is a One-Time, Single-Dose Treatment Available for Adults with Severe Hemophilia...

2023-06-29 13:27:29 ET Summary A major catalyst may arrive tomorrow for BioMarin as the FDA announces whether it will approve hemophilia gene therapy Roctavian. The drug is already approved in Europe, although pricing disputes are hindering sales. That ought not to be a problem in...

2023-06-23 15:00:37 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress PR Newswire New Data to be Presented for ROCTAVIAN fr...